TY - JOUR
T1 - Nasal Microbiome Change During and After Exacerbation in Asthmatic Children
AU - Liu, Tsunglin
AU - Lin, Cheng Han
AU - Chen, Yi Lin
AU - Jeng, Shuen Lin
AU - Tsai, Hui Ju
AU - Ho, Chung Liang
AU - Kuo, Wen Shuo
AU - Hsieh, Miao Hsi
AU - Chen, Pei Chi
AU - Wu, Lawrence Shih Hsin
AU - Wang, Jiu Yao
N1 - Funding Information:
This work was supported by the Ministry of Science and Technology (MOST) in Taiwan, and in part by the Center of Allergy and Mucosal Immunity, Headquarters of University Advancement to the NCKU, Ministry of Education, Taiwan, and Research Center for Allergy, Immunology, and Microbiology, China Medical University, Taichung, Taiwan.
Publisher Copyright:
Copyright © 2022 Liu, Lin, Chen, Jeng, Tsai, Ho, Kuo, Hsieh, Chen, Wu and Wang.
PY - 2022/3/4
Y1 - 2022/3/4
N2 - Airway and gut microbiota are important in asthma pathogenesis. Although several studies have revealed distinct microbiota in asthmatic airways at baseline compared to healthy controls, limited studies compared microbiota during acute exacerbation (AE) and in the recovery phase (RP) in the same asthmatic children. We aim to investigate association between microbiota and asthma status in children and explore their relationship with clinical features of asthma. We recruited 56 asthmatic children and investigated their nasal, throat, and stool microbiota during AE and in the RP. Totally, 320 samples were subjected to 16S rRNA sequencing. Although the microbial communities were clearly separated by body site, within each site the overall communities during AE and in the RP could not be distinguished. Most nasal microbiota were dominated by only one or two of six bacterial genera. The domination was associated with mite allergy and patient age only during AE but not in the RP. When moving into RP, the relative abundance of Staphylococcus increased while that of Moraxella decreased. Throat and stool microbiota were not associated with most of the clinical features. Interestingly, stool microbiota during AE was associated with ABO blood type and stool microbiota in the RP was associated with frequency of the subsequent exacerbations. In summary, the association between nasal microbiota and mite allergy only during AE suggests an altered local immunity and its interplay with nasal microbes. Our work provides a basis for studying microbes, and prevention or therapeutic strategy in childhood asthma, especially during AE.
AB - Airway and gut microbiota are important in asthma pathogenesis. Although several studies have revealed distinct microbiota in asthmatic airways at baseline compared to healthy controls, limited studies compared microbiota during acute exacerbation (AE) and in the recovery phase (RP) in the same asthmatic children. We aim to investigate association between microbiota and asthma status in children and explore their relationship with clinical features of asthma. We recruited 56 asthmatic children and investigated their nasal, throat, and stool microbiota during AE and in the RP. Totally, 320 samples were subjected to 16S rRNA sequencing. Although the microbial communities were clearly separated by body site, within each site the overall communities during AE and in the RP could not be distinguished. Most nasal microbiota were dominated by only one or two of six bacterial genera. The domination was associated with mite allergy and patient age only during AE but not in the RP. When moving into RP, the relative abundance of Staphylococcus increased while that of Moraxella decreased. Throat and stool microbiota were not associated with most of the clinical features. Interestingly, stool microbiota during AE was associated with ABO blood type and stool microbiota in the RP was associated with frequency of the subsequent exacerbations. In summary, the association between nasal microbiota and mite allergy only during AE suggests an altered local immunity and its interplay with nasal microbes. Our work provides a basis for studying microbes, and prevention or therapeutic strategy in childhood asthma, especially during AE.
UR - http://www.scopus.com/inward/record.url?scp=85127149416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127149416&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2021.833726
DO - 10.3389/fmicb.2021.833726
M3 - Article
AN - SCOPUS:85127149416
SN - 1664-302X
VL - 12
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 833726
ER -